S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)

INmune Bio (INMB) Stock Forecast, Price & News

$6.85
-0.16 (-2.28%)
(As of 01:04 PM ET)
Compare
Today's Range
$6.75
$7.45
50-Day Range
$6.61
$8.95
52-Week Range
$5.75
$11.26
Volume
26,389 shs
Average Volume
53,970 shs
Market Capitalization
$123.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

INmune Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
129.9% Upside
$16.00 Price Target
Short Interest
Bearish
11.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$110,100 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

767th out of 972 stocks

Biological Products, Except Diagnostic Industry

124th out of 158 stocks


INMB stock logo

About INmune Bio (NASDAQ:INMB) Stock

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Price History

INMB Stock News Headlines

Inmune Bio (INMB) Receives a Buy from BTIG
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Q2 2023 INmune Bio Inc Earnings Call
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Earnings Outlook For INmune Bio
Maxim Group Sticks to Its Buy Rating for Inmune Bio (INMB)
8-K: Inmune Bio, Inc.
See More Headlines
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Company Calendar

Last Earnings
8/07/2023
Today
9/29/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+128.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,300,000.00
Net Margins
-9,532.26%
Pretax Margin
-9,532.26%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
$3.35 per share

Miscellaneous

Free Float
11,516,000
Market Cap
$126.32 million
Optionable
Not Optionable
Beta
1.95
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Raymond Joseph Tesi M.D.Dr. Raymond Joseph Tesi M.D. (Age 67)
    Co-Founder, Pres, CEO, Chief Medical Officer & Chairman
    Comp: $591.5k
  • Mr. David J. Moss M.B.A.Mr. David J. Moss M.B.A. (Age 53)
    CFO, Treasurer & Sec.
    Comp: $445.16k
  • Dr. Mark William Lowdell BSc (Age 60)
    FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer
    Comp: $152.01k
  • Mr. Joshua S. Schoonover Esq.
    Assoc. Gen. Counsel
  • Dr. Christopher J. Barnum
    Head of Neuroscience













INMB Stock - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares.
View INMB analyst ratings
or view top-rated stocks.

What is INmune Bio's stock price forecast for 2023?

1 equities research analysts have issued 1-year price objectives for INmune Bio's shares. Their INMB share price forecasts range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 128.2% from the stock's current price.
View analysts price targets for INMB
or view top-rated stocks among Wall Street analysts.

How have INMB shares performed in 2023?

INmune Bio's stock was trading at $6.34 at the beginning of 2023. Since then, INMB shares have increased by 10.6% and is now trading at $7.01.
View the best growth stocks for 2023 here
.

When is INmune Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our INMB earnings forecast
.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.36) earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. INmune Bio had a negative trailing twelve-month return on equity of 46.30% and a negative net margin of 9,532.26%.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $7.01.

How much money does INmune Bio make?

INmune Bio (NASDAQ:INMB) has a market capitalization of $126.32 million and generates $370,000.00 in revenue each year. The company earns $-27,300,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The official website for the company is www.inmunebio.com. The company can be reached via phone at (858) 964-3720 or via email at james@haydenir.com.

This page (NASDAQ:INMB) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -